Common germline polymorphisms associated with breast cancer-specific survival. by Pirie, A et al.
Breast Cancer Research
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF
and full text (HTML) versions will be made available soon.
Common germline polymorphisms associated with breast cancer specific survival
Breast Cancer Research Sample
doi:10.1186/s13058-015-0570-7
Ailith Pirie (ap736@medschl.cam.ac.uk)
Qi Guo (qg209@medschl.cam.ac.uk)
Peter Kraft (pkraft@hsph.harvard.edu)
Sander Canisius (s.canisius@nki.nl)
Diana M Eccles (d.m.eccles@soton.ac.uk)
Nazneen Rahman (Nazneen.Rahman@icr.ac.uk)
Heli Nevanlinna (Heli.Nevanlinna@hus.fi)
Constance Chen (cjchen@hsph.harvard.edu)
Sofia Khan (sofia.khan@helsinki.fi)
Jonathan Tyrer (jpt34@medschl.cam.ac.uk)
Manjeet K Bolla (mkh39@medschl.cam.ac.uk)
Qin Wang (qw232@medschl.cam.ac.uk)
Joe Dennis (jgd29@cam.ac.uk)
Kyriaki Michailidou (km533@medschl.cam.ac.uk)
Michael Lush (mjl81@medschl.cam.ac.uk)
Alison M Dunning (amd24@medschl.cam.ac.uk)
Mitul Shah (ms483@medschl.cam.ac.uk)
Kamila Czene (kamila.czene@ki.se)
Hatef Darabi (hatef.darabi@ki.se)
Mikael Eriksson (mikael.eriksson@ki.se)
Dieter Lambrechts (diether.lambrechts@med.kuleuven.be)
Caroline Weltens (caroline.weltens@uzleuven.be)
Karin Leunen (karin.leunen@uzleuven.be)
Chantal van Ongeval (Chantal.VanOngeval@uzleuven.be)
Børge G Nordestgaard (boerge.nordestgaard@regionh.dk)
Sune F Nielsen (sune.fallgaard.nielsen@regionh.dk)
Henrik Flyger (henrik.flyger@regionh.dk)
Anja Rudolph (a.rudolph@dkfz.de)
Petra Seibold (p.seibold@dkfz.de)
Dieter Flesch-Janys (flesch@uke.uni-hamburg.de)
Carl Blomqvist (carl.blomqvist@helsinki.fi)
Kristiina Aittomäki (kristiina.aittomaki@hus.fi)
Rainer Fagerholm (Heli.Nevanlinna@hus.fi)
Taru A Muranen (taru.a.muranen@helsinki.fi)
Janet E Olsen (olsonj@mayo.edu)
Emily Hallberg (Hallberg.emily@mayo.edu)
Celine Vachon (vachon.celine@mayo.edu)
Julia A Knight (knight@lunenfeld.ca)
Gord Glendon (gglendon@uhnresearch.ca)
Anna Marie Mulligan (AnnaMarie.Mulligan@uhn.ca)
Annegien Broeks (a.broeks@nki.nl)
Sten Cornelissen (s.cornelissen@nki.nl)
Christopher A Haiman (Christopher.Haiman@med.usc.edu)
Brian E Henderson (Behender@usc.edu)
Frederick Schumacher (fschumac@usc.edu)
Loic Le Marchand (loic@crch.hawaii.edu)
 (2015) 17:58 
John L Hopper (j.hopper@unimelb.edu.au)
Helen Tsimiklis (htsi@unimelb.edu.au)
Carmel Apicella (capic@unimelb.edu.au)
Melissa C Southey (msouthey@unimelb.edu.au)
Simon S Cross (s.s.cross@sheffield.ac.uk)
Malcolm WR Reed (m.w.reed@sheffield.ac.uk)
Graham G Giles (Graham.Giles@cancervic.org.au)
Roger L Milne (Roger.Milne@cancervic.org.au)
Catriona McLean (C.McLean@alfred.org.au)
Robert Winqvist (robert.winqvist@oulu.fi)
Katri Pylkäs (katri.pylkas@oulu.fi)
Arja Jukkola-Vuorinen (arja.jukkola-vuorinen@ppshp.fi)
Mervi Grip (mervi.grip@ppshp.fi)
Maartje J Hooning (m.hooning@erasmusmc.nl)
Antoinette Hollestelle (a.hollestelle@erasmusmc.nl)
John WM Martens (j.martens@erasmusmc.nl)
Ans MW van den Ouweland (a.vandenouweland@erasmusmc.nl)
Federick Marme (frederikmarme@gmail.com)
Andreas Schneeweiss (Andreas.Schneeweiss@med.uni-heidelberg.de)
Rongxi Yang (R.Yang@dkfz.de)
Barbara Burwinkel (Barbara.Burwinkel@med.uni-heidelberg.de)
Jonine Figueroa (figueroaj@mail.nih.gov)
Stephen J Chanock (chanocks@mail.nih.gov)
Jolanta Lissowska (lissowsj@coi.waw.pl)
Elinor J Sawyer (chanocks@mail.nih.gov)
Ian Tomlinson (iant@well.ox.ac.uk)
Michael J Kerin (michael.kerin@nuigalway.ie)
Nicola Miller (nicola.miller@nuigalway.ie)
Hermann Brenner (h.brenner@dkfz.de)
Katja Butterbach (k.butterbach@dkfz.de)
Bernd Holleczek (b.holleczek@gbe-ekr.saarland.de)
Vesa Kataja (vesa.kataja@kuh.fi)
Veli-Matti Kosma (veli-matti.kosma@uef.fi)
Jaana M Hartikainen (jaana.hartikainen@uef.fi)
Jingmei Li (jingmei@gmail.com)
Judith S Brand (judith.brand@ki.se)
Keith Humphreys (Keith.Humphreys@ki.se)
Peter Devilee (p.devilee@lumc.nl)
Robert AEM Tollenaar (r.a.e.m.tollenaar@lumc.nl)
Caroline Seynaeve (c.seynaeve@erasmusmc.nl)
Paolo Radice (paolo.radice@istitutotumori.mi.it)
Paolo Peterlongo (paolo.peterlongo@ifom.eu)
Siranoush Manoukian (siranoush.manoukian@istitutotumori.mi.it)
Filomena Ficarazzi (filomena.ficarazzi@ifom.eu)
Matthias W Beckmann (fk-direktion@uk-erlangen.de)
Alexander Hein (alexander.hein@uk-erlangen.de)
Arif B Ekici (arif.ekici@uk-erlangen.de)
Rosemary Balleine (rosemary.balleine@sydney.edu.au)
Kelly-Anne Phillips (Kelly.Phillips@petermac.org)
Javier Benitez (jbenitez@cnio.es)
M Pilar Zamora (zamorapilar@gmail.com)
Jose Ignacio Arias Perez (jiarias@msn.com)
Primitiva Menéndez (tiva@hca.es)
Anna Jakubowska (aniaj@sci.pam.szczecin.pl)
Jan Lubinski (lubinski@sci.pam.szczecin.pl)
Jacek Gronwald (jgron@sci.pum.edu.pl)
Katarzyna Durda (k.durda@onet.pl)
Ute Hamann (u.hamann@dkfz-heidelberg.de)
Maria Kabisch (m.kabisch@dkfz-heidelberg.de)
Hans Ulrich Ulmer (hu.ulmer@klinikum-mittelbaden.de)
Thomas Rüdiger (Thomas.Ruediger@klinikum-karlsruhe.de)
Sara Margolin (Sara.Margolin@karolinska.se)
Vessela Kristensen (Vessela.N.Kristensen@rr-research.no)
Siljie Nord (silje.nordgard@gmail.com)
D Gareth Evans (Gareth.Evans@cmft.nhs.uk)
Jean Abraham (ja344@medschl.cam.ac.uk)
Helena Earl (hme22@cam.ac.uk)
Christopher J Poole (christopher.poole@warwick.ac.uk)
Louise Hiller (l.hiller@warwick.ac.uk)
Janet A Dunn (j.a.dunn@warwick.ac.uk)
Sarah Bowden (s.j.bowden@bham.ac.uk)
Rose Yang (royang@mail.nih.gov)
Daniele Campa (d.campa@dkfz-heidelberg.de)
W Ryan Diver (Ryan.diver@cancer.org)
Susan M Gapstur (Susan.gapstur@cancer.org)
Mia M Gaudet (Mia.gaudet@cancer.org)
Susan Hankinson (shankinson@schoolph.umass.edu)
Robert N Hoover (hooverr@exchange.nih.gov)
Anika Hüsing (a.huesing@dkfz.de)
Rudolf Kaaks (r.kaaks@dkfz.de)
Mitchell J Machiela (Mitchell.machiela@nih.gov)
Walter Willett (wwillett@hsph.harvard.edu)
Myrto Barrdahl (m.barrdahl@Dkfz-Heidelberg.de)
Federico Canzian (f.canzian@dkfz-heidelberg.de)
Suet-Feung Chin (Suet-Feung.Chin@cruk.cam.ac.uk)
Carlos Caldas (carlos.caldas@cruk.cam.ac.uk)
David J Hunter (dhunter@hsph.harvard.edu)
Sara Lindstrom (slindstr@hsph.harvard.edu)
Montserrat Garcia-Closas (Montse.GarciaClosas@icr.ac.uk)
Fergus J Couch (couch.fergus@mayo.edu)
Georgia Chenevix-Trench (Georgia.Trench@qimrberghofer.edu.au)
Arto Mannermaa (arto.mannermaa@uef.fi)
Irene L Andrulis (andrulis@lunenfeld.ca)
Per Hall (Per.Hall@ki.se)
Jenny Chang-Claude (j.chang-claude@dkfz-heidelberg.de)
Douglas F Easton (dfe20@medschl.cam.ac.uk)
Stig E Bojesen (stig.egil.bojesen@regionh.dk)
Angela Cox (a.cox@shef.ac.uk)
Peter A Fasching (peter.fasching@uk-erlangen.de)
Paul DP Pharoah (pp10001@medschl.cam.ac.uk)
Marjanka K Schmidt (mk.schmidt@nki.nl)
kConFab Investigators (Georgia.Trench@qimrberghofer.edu.au)
NBCS Investigators (Vessela.N.Kristensen@rr-research.no)
Sample
ISSN 1465-5411
Article type Research article
Submission date 7 November 2014
Acceptance date 10 April 2015
Article URL http://dx.doi.org/10.1186/s13058-015-0570-7
For information about publishing your research in BioMed Central journals, go to
http://www.biomedcentral.com/info/authors/
© 2015 Pirie et al.; licensee BioMed Central.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Common germline polymorphisms associated with 
breast cancer specific survival 
Ailith Pirie1,96* 
* Corresponding author 
Email: ap736@medschl.cam.ac.uk 
Qi Guo2 
Email: qg209@medschl.cam.ac.uk 
Peter Kraft3,4 
Email: pkraft@hsph.harvard.edu 
Sander Canisius5 
Email: s.canisius@nki.nl 
Diana M Eccles6 
Email: d.m.eccles@soton.ac.uk 
Nazneen Rahman7 
Email: Nazneen.Rahman@icr.ac.uk 
Heli Nevanlinna8 
Email: Heli.Nevanlinna@hus.fi 
Constance Chen3 
Email: cjchen@hsph.harvard.edu 
Sofia Khan8 
Email: sofia.khan@helsinki.fi 
Jonathan Tyrer2 
Email: jpt34@medschl.cam.ac.uk 
Manjeet K Bolla1 
Email: mkh39@medschl.cam.ac.uk 
Qin Wang1 
Email: qw232@medschl.cam.ac.uk 
Joe Dennis1 
Email: jgd29@cam.ac.uk 
Kyriaki Michailidou1 
Email: km533@medschl.cam.ac.uk 
Michael Lush1 
Email: mjl81@medschl.cam.ac.uk 
Alison M Dunning2 
Email: amd24@medschl.cam.ac.uk 
Mitul Shah2 
Email: ms483@medschl.cam.ac.uk 
Kamila Czene9 
Email: kamila.czene@ki.se 
Hatef Darabi9 
Email: hatef.darabi@ki.se 
Mikael Eriksson9 
Email: mikael.eriksson@ki.se 
Dieter Lambrechts10,11 
Email: diether.lambrechts@med.kuleuven.be 
Caroline Weltens12 
Email: caroline.weltens@uzleuven.be 
Karin Leunen12 
Email: karin.leunen@uzleuven.be 
Chantal van Ongeval12 
Email: Chantal.VanOngeval@uzleuven.be 
Børge G Nordestgaard13,14,15 
Email: boerge.nordestgaard@regionh.dk 
Sune F Nielsen13,14 
Email: sune.fallgaard.nielsen@regionh.dk 
Henrik Flyger16 
Email: henrik.flyger@regionh.dk 
Anja Rudolph17 
Email: a.rudolph@dkfz.de 
Petra Seibold17 
Email: p.seibold@dkfz.de 
Dieter Flesch-Janys18 
Email: flesch@uke.uni-hamburg.de 
Carl Blomqvist19 
Email: carl.blomqvist@helsinki.fi 
Kristiina Aittomäki20 
Email: kristiina.aittomaki@hus.fi 
Rainer Fagerholm8,19,20 
Email: Heli.Nevanlinna@hus.fi 
Taru A Muranen8 
Email: taru.a.muranen@helsinki.fi 
Janet E Olsen21 
Email: olsonj@mayo.edu 
Emily Hallberg22 
Email: Hallberg.emily@mayo.edu 
Celine Vachon21 
Email: vachon.celine@mayo.edu 
Julia A Knight23,24 
Email: knight@lunenfeld.ca 
Gord Glendon25 
Email: gglendon@uhnresearch.ca 
Anna Marie Mulligan26,27 
Email: AnnaMarie.Mulligan@uhn.ca 
Annegien Broeks5 
Email: a.broeks@nki.nl 
Sten Cornelissen5 
Email: s.cornelissen@nki.nl 
Christopher A Haiman28 
Email: Christopher.Haiman@med.usc.edu 
Brian E Henderson28 
Email: Behender@usc.edu 
Frederick Schumacher28 
Email: fschumac@usc.edu 
Loic Le Marchand29 
Email: loic@crch.hawaii.edu 
John L Hopper30 
Email: j.hopper@unimelb.edu.au 
Helen Tsimiklis31 
Email: htsi@unimelb.edu.au 
Carmel Apicella30 
Email: capic@unimelb.edu.au 
Melissa C Southey31 
Email: msouthey@unimelb.edu.au 
Simon S Cross32 
Email: s.s.cross@sheffield.ac.uk 
Malcolm WR Reed33 
Email: m.w.reed@sheffield.ac.uk 
Graham G Giles30,34 
Email: Graham.Giles@cancervic.org.au 
Roger L Milne30,34 
Email: Roger.Milne@cancervic.org.au 
Catriona McLean35 
Email: C.McLean@alfred.org.au 
Robert Winqvist36 
Email: robert.winqvist@oulu.fi 
Katri Pylkäs36 
Email: katri.pylkas@oulu.fi 
Arja Jukkola-Vuorinen37 
Email: arja.jukkola-vuorinen@ppshp.fi 
Mervi Grip38 
Email: mervi.grip@ppshp.fi 
Maartje J Hooning39 
Email: m.hooning@erasmusmc.nl 
Antoinette Hollestelle39 
Email: a.hollestelle@erasmusmc.nl 
John WM Martens39 
Email: j.martens@erasmusmc.nl 
Ans MW van den Ouweland39 
Email: a.vandenouweland@erasmusmc.nl 
Federick Marme40,41 
Email: frederikmarme@gmail.com 
Andreas Schneeweiss40,41 
Email: Andreas.Schneeweiss@med.uni-heidelberg.de 
Rongxi Yang40 
Email: R.Yang@dkfz.de 
Barbara Burwinkel40,42 
Email: Barbara.Burwinkel@med.uni-heidelberg.de 
Jonine Figueroa43 
Email: figueroaj@mail.nih.gov 
Stephen J Chanock43,44 
Email: chanocks@mail.nih.gov 
Jolanta Lissowska45 
Email: lissowsj@coi.waw.pl 
Elinor J Sawyer46 
Email: chanocks@mail.nih.gov 
Ian Tomlinson47 
Email: iant@well.ox.ac.uk 
Michael J Kerin48 
Email: michael.kerin@nuigalway.ie 
Nicola Miller48 
Email: nicola.miller@nuigalway.ie 
Hermann Brenner49,50 
Email: h.brenner@dkfz.de 
Katja Butterbach49 
Email: k.butterbach@dkfz.de 
Bernd Holleczek51 
Email: b.holleczek@gbe-ekr.saarland.de 
Vesa Kataja52 
Email: vesa.kataja@kuh.fi 
Veli-Matti Kosma53,54 
Email: veli-matti.kosma@uef.fi 
Jaana M Hartikainen53,54 
Email: jaana.hartikainen@uef.fi 
Jingmei Li9 
Email: jingmei@gmail.com 
Judith S Brand9 
Email: judith.brand@ki.se 
Keith Humphreys9 
Email: Keith.Humphreys@ki.se 
Peter Devilee55 
Email: p.devilee@lumc.nl 
Robert AEM Tollenaar56 
Email: r.a.e.m.tollenaar@lumc.nl 
Caroline Seynaeve39 
Email: c.seynaeve@erasmusmc.nl 
Paolo Radice57 
Email: paolo.radice@istitutotumori.mi.it 
Paolo Peterlongo58 
Email: paolo.peterlongo@ifom.eu 
Siranoush Manoukian59 
Email: siranoush.manoukian@istitutotumori.mi.it 
Filomena Ficarazzi58,60 
Email: filomena.ficarazzi@ifom.eu 
Matthias W Beckmann61 
Email: fk-direktion@uk-erlangen.de 
Alexander Hein61 
Email: alexander.hein@uk-erlangen.de 
Arif B Ekici62 
Email: arif.ekici@uk-erlangen.de 
Rosemary Balleine63 
Email: rosemary.balleine@sydney.edu.au 
Kelly-Anne Phillips30,64,65 
Email: Kelly.Phillips@petermac.org 
kConFab Investigators64 
Email: Georgia.Trench@qimrberghofer.edu.au 
Javier Benitez66,67 
Email: jbenitez@cnio.es 
M Pilar Zamora68 
Email: zamorapilar@gmail.com 
Jose Ignacio Arias Perez69 
Email: jiarias@msn.com 
Primitiva Menéndez70 
Email: tiva@hca.es 
Anna Jakubowska71 
Email: aniaj@sci.pam.szczecin.pl 
Jan Lubinski71 
Email: lubinski@sci.pam.szczecin.pl 
Jacek Gronwald71 
Email: jgron@sci.pum.edu.pl 
Katarzyna Durda71 
Email: k.durda@onet.pl 
Ute Hamann72 
Email: u.hamann@dkfz-heidelberg.de 
Maria Kabisch72 
Email: m.kabisch@dkfz-heidelberg.de 
Hans Ulrich Ulmer73 
Email: hu.ulmer@klinikum-mittelbaden.de 
Thomas Rüdiger74 
Email: Thomas.Ruediger@klinikum-karlsruhe.de 
Sara Margolin75 
Email: Sara.Margolin@karolinska.se 
Vessela Kristensen76,77 
Email: Vessela.N.Kristensen@rr-research.no 
Siljie Nord76,77 
Email: silje.nordgard@gmail.com 
NBCS Investigators76 
Email: Vessela.N.Kristensen@rr-research.no 
D Gareth Evans78 
Email: Gareth.Evans@cmft.nhs.uk 
Jean Abraham2,79,80 
Email: ja344@medschl.cam.ac.uk 
Helena Earl79,80 
Email: hme22@cam.ac.uk 
Christopher J Poole81 
Email: christopher.poole@warwick.ac.uk 
Louise Hiller81 
Email: l.hiller@warwick.ac.uk 
Janet A Dunn81 
Email: j.a.dunn@warwick.ac.uk 
Sarah Bowden82 
Email: s.j.bowden@bham.ac.uk 
Rose Yang83 
Email: royang@mail.nih.gov 
Daniele Campa17,84 
Email: d.campa@dkfz-heidelberg.de 
W Ryan Diver85 
Email: Ryan.diver@cancer.org 
Susan M Gapstur85 
Email: Susan.gapstur@cancer.org 
Mia M Gaudet85 
Email: Mia.gaudet@cancer.org 
Susan Hankinson4,86,87 
Email: shankinson@schoolph.umass.edu 
Robert N Hoover43 
Email: hooverr@exchange.nih.gov 
Anika Hüsing17 
Email: a.huesing@dkfz.de 
Rudolf Kaaks17 
Email: r.kaaks@dkfz.de 
Mitchell J Machiela43 
Email: Mitchell.machiela@nih.gov 
Walter Willett88 
Email: wwillett@hsph.harvard.edu 
Myrto Barrdahl17 
Email: m.barrdahl@Dkfz-Heidelberg.de 
Federico Canzian89 
Email: f.canzian@dkfz-heidelberg.de 
Suet-Feung Chin90 
Email: Suet-Feung.Chin@cruk.cam.ac.uk 
Carlos Caldas79,80,90 
Email: carlos.caldas@cruk.cam.ac.uk 
David J Hunter4,91 
Email: dhunter@hsph.harvard.edu 
Sara Lindstrom4,91 
Email: slindstr@hsph.harvard.edu 
Montserrat Garcia-Closas7,92 
Email: Montse.GarciaClosas@icr.ac.uk 
Fergus J Couch22 
Email: couch.fergus@mayo.edu 
Georgia Chenevix-Trench93 
Email: Georgia.Trench@qimrberghofer.edu.au 
Arto Mannermaa53,54 
Email: arto.mannermaa@uef.fi 
Irene L Andrulis25,94 
Email: andrulis@lunenfeld.ca 
Per Hall9 
Email: Per.Hall@ki.se 
Jenny Chang-Claude17 
Email: j.chang-claude@dkfz-heidelberg.de 
Douglas F Easton1,2 
Email: dfe20@medschl.cam.ac.uk 
Stig E Bojesen13,14,15 
Email: stig.egil.bojesen@regionh.dk 
Angela Cox33 
Email: a.cox@shef.ac.uk 
Peter A Fasching62,95 
Email: peter.fasching@uk-erlangen.de 
Paul DP Pharoah1,2 
Email: pp10001@medschl.cam.ac.uk 
Marjanka K Schmidt5,96* 
* Corresponding author 
Email: mk.schmidt@nki.nl 
1 Centre for Cancer Genetic Epidemiology, Department of Public Health and 
Primary Care, University of Cambridge, Cambridge, UK 
2 Centre for Cancer Genetic Epidemiology, Department of Oncology, University 
of Cambridge, Cambridge, UK 
3 Program in Genetic Epidemiology and Statistical Genetics, Department of 
Epidemiology, Harvard School of Public Health, Boston, MA, USA 
4 Department of Epidemiology, Harvard School of Public Health, Boston, MA, 
USA 
5 Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, 
The Netherlands 
6 Faculty of Medicine, University of Southampton, Southampton, UK 
7 Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, 
Surrey, UK 
8 Department of Obstetrics and Gynecology, University of Helsinki and Helsinki 
University Central Hospital, Helsinki, Finland 
9 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
Stockholm 17177, Sweden 
10 Vesalius Research Center (VRC), Vib, Leuven, Belgium 
11 Laboratory for Translational Genetics, Department of Oncology, University of 
Leuven, Leuven, Belgium 
12 Oncology Department, University Hospital Gasthuisberg, Leuven, Belgium 
13 Copenhagen General Population Study, Herlev Hospital, Copenhagen 
University Hospital, University of Copenhagen, Copenhagen, Denmark 
14 Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University 
Hospital, University of Copenhagen, Copenhagen, Denmark 
15 Faculty of Health and Medical Sciences, University of Copenhagen, 
Copenhagen, Denmark 
16 Department of Breast Surgery, Herlev Hospital, Copenhagen University 
Hospital, Copenhagen, Denmark 
17 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
Heidelberg, Germany 
18 Department of Cancer Epidemiology/Clinical Cancer Registry and Institute for 
Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, 
Hamburg, Germany 
19 Department of Oncology, Helsinki University Central Hospital, Helsinki, 
Finland 
20 Department of Clinical Genetics, Helsinki University Central Hospital, 
Helsinki, Finland 
21 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA 
22 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, 
MN, USA 
23 Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research 
Institute, Mount Sinai Hospital, Toronto, Ontario, Canada 
24 Division of Epidemiology, Dalla Lana School of Public Health, University of 
Toronto, Toronto, Ontario, Canada 
25 Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute, 
Mount Sinai Hospital, Toronto, Ontario, Canada 
26 Department of Laboratory Medicine and Pathobiology, University of Toronto, 
Toronto, Ontario, Canada 
27 Laboratory Medicine Program, University Health Network, Toronto, Ontario, 
Canada 
28 Department of Preventive Medicine, Keck School of Medicine, University of 
Southern California, Los Angeles, CA, USA 
29 Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii 
96813, USA 
30 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, 
Melbourne School of Population Health, the University of Melbourne, 
Melbourne, Australia 
31 Department of Pathology, the University of Melbourne, Melbourne, Australia 
32 Academic Unit of Pathology, Department of Neuroscience, University of 
Sheffield, Sheffield, UK 
33 CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, 
University of Sheffield, Sheffield, UK 
34 Cancer Epidemiology Centre, the Cancer Council Victoria, Melbourne, 
Australia 
35 Anatomical Pathology, the Alfred Hospital, Melbourne, Australia 
36 Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical 
Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, 
Oulu, Finland 
37 Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, 
Finland 
38 Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, 
Finland 
39 Department of Medical Oncology, Family Cancer Clinic, Erasmus Mc Cancer 
Institute, Rotterdam, The Netherlands 
40 Department of Obstetrics and Gynecology, University of Heidelberg, 
Heidelberg, Germany 
41 National Center for Tumor Diseases, University of Heidelberg, Heidelberg, 
Germany 
42 Molecular Epidemiology Group, German Cancer Research Center (DKFZ), 
Heidelberg, Germany 
43 Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
Bethesda, MD, USA 
44 Core Genotyping Facility, Frederick National Laboratory for Cancer Research, 
Gaithersburg, MD, USA 
45 Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie 
Memorial Cancer Center & Institute of Oncology, Warsaw, Poland 
46 Division of Cancer Studies, Nihr Comprehensive Biomedical Research Centre, 
Guy’s & St. Thomas’ NHS Foundation Trust in Partnership with King’s College 
London, London, UK 
47 Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research 
Centre, University of Oxford, Oxford, UK 
48 Clinical Science Institute, University Hospital Galway, Galway, Ireland 
49 Division of Clinical Epidemiology and Aging Research, German Cancer 
Research Center (DKFZ), Heidelberg, Germany 
50 German Cancer Consortium (DKTK), Heidelberg, Germany 
51 Saarland Cancer Registry, Saarbrücken, Germany 
52 School of Medicine, Institute of Clinical Medicine, Oncology and Cancer 
Center, Kuopio University Hospital, Kuopio, Finland 
53 School of Medicine, Institute of Clinical Medicine, Pathology and Forensic 
Medicine and Cancer Center of Eastern Finland, University of Eastern Finland, 
Kuopio, Finland 
54 Imaging Center, Department of Clinical Pathology, Kuopio University 
Hospital, Kuopio, Finland 
55 Department of Human Genetics & Department of Pathology, Leiden University 
Medical Center, 2300 RC Leiden, The Netherlands 
56 Department of Surgical Oncology, Leiden University Medical Center, 2300 RC 
Leiden, The Netherlands 
57 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of 
Preventive and Predictive Medicine, Fondazione Irccs Istituto Nazionale Dei 
Tumori (INT), Milan, Italy 
58 IFOM, Fondazione Istituto Firc Di Oncologia Molecolare, Milan, Italy 
59 Unit of Medical Genetics, Department of Preventive and Predictive Medicine, 
Fondazione IRCCS Istituto Nazionale Dei Tumori (INT), Milan, Italy 
60 Cogentech Cancer Genetic Test Laboratory, 20139 Milan, Italy 
61 Department of Gynecology and Obstetrics, University Hospital Erlangen, 
Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer 
Center Erlangen-Emn, Erlangen, Germany 
62 Institute of Human Genetics; University Hospital Erlangen, Friedrich-
Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center 
Erlangen-Emn, Erlangen, Germany 
63 Western Sydney and Nepean Blue Mountains Local Health Districts, 
Westmead Millennium Institute for Medical Research, University of Sydney, 
Sydney, Australia 
64 Peter Maccallum Cancer Center, Melbourne, Australia 
65 Sir Peter Maccallum Department of Oncology, University of Melbourne, 
Melbourne, Australia 
66 Human Genetics Group, Human Cancer Genetics Program, Spanish National 
Cancer Research Centre (CNIO), Madrid, Spain 
67 Centro De Investigación En Red De Enfermedades Raras (CIBERER), 
Valencia, Spain 
68 Servicio De Oncología Médica, Hospital Universitario La Paz, Madrid, Spain 
69 Servicio De Cirugía General Y Especialidades, Hospital Monte Naranco, 
Oviedo, Spain 
70 Servicio De Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain 
71 Department of Genetics and Pathology, Pomeranian Medical University, 
Szczecin, Poland 
72 Molecular Genetics of Breast Cancer, German Cancer Research Center 
(DKFZ), Heidelberg, Germany 
73 Frauenklinik der Stadtklinik Baden-Baden, Baden-Baden, Germany 
74 Institute of Pathology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany 
75 Department of Oncology - Pathology, Karolinska Institutet, Stockholm, 
Sweden 
76 Faculty of Medicine (Faculty Division Ahus), University of Oslo (UiO), Oslo, 
Norway 
77 Department of Genetics, Institute for Cancer Research, Oslo University 
Hospital, Radiumhospitalet, Oslo, Norway 
78 Genomic Medicine, Manchester Academic Health Science Centre, University 
of Manchester, Central Manchester Foundation Trust, St. Mary’s Hospital, 
Oxford Road, Manchester M13 9wl, UK 
79 Cambridge Experimental Cancer Medicine Centre, Cambridge, UK 
80 Cambridge Breast Unit and NIHR Cambridge Biomedical Research Centre, 
University of Cambridge NHS Foundation Hospitals, Hills Road, Cambridge, UK 
81 Warwick Clinical Trials Unit, University of Warwick, Warwick, UK 
82 Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, the 
University of Birmingham, Edgbaston, Birmingham, UK 
83 Early Detection Research Group, Division of Cancer Prevention National 
Cancer Institute Bethesda, Maryland, USA 
84 Department of Biology, University of Pisa, Pisa, Italy 
85 Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA 
86 Division of Biostatistics and Epidemiology, University of Massachusetts-
Amherst School of Public Health and Health Sciences, Amherst, MA, USA 
87 Channing Division of Network Medicine, Department of Medicine, Brigham 
and Women’s Hospital, Boston, MA, USA 
88 Department of Nutrition, Harvard School of Public Health, Boston, MA, USA 
89 Genomic Epidemiology Group, German Cancer Research Center (DKFZ), 
Heidelberg, Germany 
90 Breast Cancer Functional Genomics Laboratory, Cancer Research UK 
Cambridge Institute, University of Cambridge, Li Ka Shing Centre, UK 
91 Program in Molecular and Genetic Epidemiology, Harvard School of Public 
Health, Boston, MA, USA 
92 Breakthrough Breast Cancer Research Centre, Division of Breast Cancer 
Research, the Institute of Cancer Research, London, UK 
93 Department of Genetics, Qimr Berghofer Medical Research Institute, Brisbane, 
Australia 
94 Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
Canada 
95 David Geffen School of Medicine, Department of Medicine, Division of 
Hematology and Oncology, University of California at Los Angeles, Los 
Angeles, CA, USA 
96 Centre for Cancer Genetic Epidemiology, University of Cambridge, 
Strangeways’ Research Laboratory, 2 Worts’ Causeway, Cambridge CB1 8RN, 
UK 
Abstract 
Introduction 
Previous studies have identified common germline variants nominally associated with breast 
cancer survival. These associations have not been widely replicated in further studies. The 
purpose of this study was to evaluate the association of previously reported SNPs with breast 
cancer specific survival using data from a pooled analysis of eight breast cancer survival 
genome-wide association studies (GWAS) from the Breast Cancer Association Consortium. 
Methods 
A literature review was conducted of all previously published associations between common 
germline variants and three survival outcomes: breast cancer specific survival, overall 
survival and disease-free survival. All associations which reached the nominal significance 
level of p-value < 0.05 were included. Single nucleotide polymorphisms that had been 
previously reported as nominally associated with at least one survival outcome were 
evaluated in the pooled analysis of over 37,000 breast cancer cases for association with breast 
cancer specific survival. Previous associations were evaluated using a one-sided test based on 
the reported direction of effect. 
Results 
Fifty-six variants from 45 previous publications were evaluated in the meta-analysis. Fifty-
four of these were evaluated in the full set of 37,954 breast cancer cases with 2,900 events 
and the two additional variants were evaluated in a reduced sample size of 30,000 samples in 
order to ensure independence from the previously published studies. Five variants reached 
nominal significance (p < 0.05) in the pooled GWAS data compared to 2.8 expected under 
the null hypothesis. Seven additional variants were associated (p < 0.05) with ER positive 
disease. 
Conclusions 
Although no variants reached genome-wide significance (p < 5 x 10−8), these results suggest 
that there is some evidence of association between candidate common germline variants and 
breast cancer prognosis. Larger studies from multi-national collaborations are necessary to 
increase the power to detect associations, between common variants and prognosis, at more 
stringent significance levels. 
Introduction 
Breast cancer is the most commonly diagnosed cancer in women, in the world, with an 
estimated 1.67 million new cancer cases diagnosed in 2012. Breast cancer mortality is the 
second most common cancer-related death in women in the more developed regions of the 
world and accounts for 15.4% of cancer related deaths in women [1]. Breast cancer outcome 
is affected by several factors including: age, tumour size, tumour grade, extent of local and 
distal spread at diagnosis, ER status, HER2 status and treatment received. It is also likely that 
inherited host characteristics, such as genetic variants, are important [2]. 
The association between common germline genetic variation and breast cancer survival has 
been examined in many candidate gene studies investigating genes in pathways known to be 
involved in breast cancer [3]. These studies have identified numerous single nucleotide 
polymorphisms (SNPs) associated with outcome at nominal significance levels, but none 
have been widely replicated in further studies. The exceptions to this are three genome-wide 
association studies [4-6] and a study from the Breast Cancer Association Consortium 
(BCAC), which had substantial power to detect associated variants with large effect sizes 
(HR > 2) [7]. Two of those genome-wide association studies have reported significant 
associations for three polymorphisms (rs9934948, rs3784099, rs4778137) [4,6]. The aim of 
this study was to evaluate the association of previously reported SNPs with prognosis using 
data from a hypothesis-generating pooled analysis of eight breast cancer survival GWAS 
from ten studies including 37,954 breast cancer cases [Guo, Schmidt, Pharoah et al., in press]. 
  
Methods 
Literature review 
Studies reporting common polymorphisms associated with breast cancer prognosis were 
identified by searching both Google Scholar and Pubmed. We searched Google Scholar using 
the search terms: “breast cancer”, “survival”, “prognosis”, “polymorphisms” and “SNPs”. 
The search terms for Pubmed were “breast cancer” AND (“survival” OR “prognosis”) AND 
(“polymorphism” OR “SNP”). The references of all identified studies were then individually 
interrogated for any additional studies. The search was last updated on 6th June 2014. We 
considered studies to be eligible for inclusion if they reported an association between a 
germline genetic variant and at least one of the following end-points: overall survival, 
disease-free survival and breast cancer specific survival. Studies evaluating the prognostic 
importance of rare high penetrance variants with minor allele frequency < 2% in BRCA1, 
BRCA2 and CHEK2 were omitted from the review. Only one study conducted ER subtype 
specific analyses. 
For the purposes of comparison, all studies that used genetic models that grouped together 
two genotypes into a single category were defined as using 'dominance models'. This 
category includes both dominant and recessive models as each study's definition of a 
dominant or recessive model is dependent on which allele is the major or minor allele, 
whether they consider the effect allele to be bi-directional, or whether they focus on only the 
risk allele. 
Genome-wide association studies 
We used data from a combined analysis of eight breast cancer GWAS, from ten studies [8-
18], that had genotype data from a genome-wide SNP array and had collected follow-up time 
data for the 37,954 breast cancer cases [Guo, Schmidt, Pharoah et al., in press]. Genotype and 
sample quality control were carried out separately for each study. In short, SNPs were 
excluded based on: low call rate, minor allele frequency < 1% and significant deviation of 
genotype frequencies from Hardy-Weinberg equilibrium. Samples were excluded for: low 
call rate, ambiguous gender, relatedness and extreme heterozygosity. We also excluded 
subjects of less than 90% European ancestry. Sample ancestry was determined separately for 
each GWAS included in the meta-analysis using either principal component analysis, multi-
dimensional scaling or LAMP based on ethnicities from HapMap samples. Samples with less 
than 90% European ancestry were excluded. As different genotyping arrays had been used for 
the different studies imputation had been performed using a reference panel from the 1000 
Genomes Project [19] [Guo,Schmidt,Pharoah et al., in press]. We utilised the imputed data 
for the SNPs of interest in this study. Details of the pooled studies are shown in Additional 
files 1 and 2. 
Cox proportional hazards models were fitted to assess the association of genotype with breast 
cancer specific mortality under a co-dominant (log-additive) genetic model using the 
likelihood ratio test. The models were adjusted for principal components in order to minimise 
the effect of population sub-structure, and the COGS (Collaborative Oncological Gene-
environment Study) [15] dataset was stratified by study. Each survival GWAS was analysed 
separately and the results were harmonized and combined using a standard inverse-variance 
weighted fixed effects meta-analysis. In order to compare the results with the published 
associations we used a one-sided test based on the reported direction of effect. In the initial 
analysis for all 56 SNPs models were unadjusted for prognostic factors. However, we 
conducted multivariable analysis of the previously reported SNPs that were significantly 
associated with survival adjusting for age, stage and grade using 29,360 samples from the 
COGS study. 
Results 
Literature review 
We identified 46 publications reporting nominally significant associations between 62 
germline variants and survival after a breast cancer diagnosis. Details of each variant and the 
reported association with breast cancer prognosis are shown in Additional file 3. The median 
sample size was 890 cases, the smallest study had 85 cases and the largest 25,853. Fifty-nine 
variants were from 44 candidate gene studies and three variants were identified through 
GWAS. The candidate genes were involved in the following pathways: DNA repair, cell 
cycle control, matrix metalloproteinases, immune response, drug response, tumour-
progression, vitamin D receptors and miscellaneous other pathways (Table 1). Findings from 
the identified publications were infrequently replicated; only six variants out of the 62 were 
reported in at least one subsequent publication. 
Table 1 Previously identified breast cancer survival genes in cancer related pathways 
Pathway Nearest Gene References
DNA Repair XRCC1, XRCC2, XRCC3, RAD51B, LIG4, ERCC2 [6,27-31] 
Cell Cycle Control CCND1, CCND3, PRKAG2, TP53, SIPA1, FGFR2, PPP2R2B [27,32-38] 
Matrix Metalloproteinases MMP7, MMP8, MMP2, SERPINE1, TIMP-3 [22,39-43] 
Immune and Drug response, 
metabolism 
Il-10, IL-6, IL-21, MPO, GSTP1, COMT, CYP19A1, CYP1A1, 
SULT1E1, NEF2L2, TLR4, SLC28A3, CD24, CD44, NQO1 
[13,21,23,44-56] 
Tumour-progression NOS3, VEGF, NME1, SELE, GNAS1, ZFP36, TGF [57-63] 
Vitamin D Receptors RXRA, VDR [64,65] 
Miscellaneous TOX3, MTHFR, COX11, OCA2, PLAUR. [4,7,33,64,66] 
NB – the genes mentioned here are the candidate genes listed in the previous publications or are the nearest gene 
to the SNP and are not necessarily the genes that the SNPs have a functional effect on. 
Meta-analysis findings 
Results from the GWAS meta-analysis included 58 of the 62 previously identified variants 
discussed above. The SNP (rs2886162) was replaced by a perfectly correlated tagSNP 
(rs2364725, r2 = 1). Associations for four of the variants identified: rs4778137 in OCA2, 
rs3803662 in TOX3, rs1042522 in TP53 and rs2479717 in CCND1 were discovered in studies 
carried out by the Breast Cancer Association Consortium using sets of samples included in 
our GWAS meta-analysis. Therefore, we are unable to replicate these associations 
independently in the full dataset. The substantial sample overlap between the studies that 
identified associations with rs4778137 and rs3803662 means that there is little to be gained 
by attempting to replicate their associations in the additional samples included in the meta-
analysis. However, the sample sizes in the studies identifying rs1042522 and rs2479717 were 
relatively small so we evaluated their association with breast cancer specific survival in the 
GWAS meta-analysis omitting the samples from studies used in the original publications. 
The two SNPs were evaluated in 29,224 and 31,434 samples respectively. 
The results for the 56 SNPs evaluated in the meta-analysis are presented in Additional file 4. 
In the analysis of all cases, five SNPs (rs2981582, rs1800566, rs9934948, rs1800470 and 
rs3775775) were significant with one-sided p-value < 0.05, 51 SNPs were not significant at 
this nominal p-value. The most significant association was for rs2981582 in FGFR2 (per G 
allele HR 1.09, 90% CI 1.04-1.14, one-sided p-value = 0.00085). All significantly associated 
SNPs had good imputation quality (r2 = 0.9-1). The imputation r2 for all 56 SNPs can be 
found in Additional file 4. No single SNP reached the stringent level of significance generally 
regarded as genome-wide significant (p-value < 5x10−8) but the number of moderately 
significant associations (5) was somewhat greater than that expected by chance (2.8). This is 
illustrated by the quantile-quantile plot shown in Figure 1. Seven SNPs not significantly 
associated with prognosis in all patients were significant in ER-positive disease. We found 
evidence of ER-positive specific associations with prognosis for 7 out of the 12 SNPs 
nominally associated (p < 0.05) with survival. These SNPs were not previously identified in 
patients with specifically ER positive disease however, our observations may agree with the 
previously reported results as most breast cancers are ER positive. We measured the level of 
heterogeneity between the studies included in the pooled analysis for the 12 SNPs associated 
with survival. There was moderate evidence of heterogeneity for the SNP rs2981582 (I2 = 
41.1%, p-value = 0.084). For all other SNPs there was low heterogeneity (I2 < 25%, p-value > 
0.2). Details of the SNPs nominally associated with breast cancer specific survival are shown 
in Table 2. The results for the nominally associated SNPs adjusted for age, stage and grade 
are shown in Additional file 5. The hazard ratios for some of the SNPs were attenuated after 
adjustment. Also, the associations with breast cancer specific survival of SNPs rs3775775 
and rs2333227 were stronger in the multivariable analysis. 
Figure 1 Quantile-quantile plot of results from look-up of previously reported associations in 
GWAS. Tests were one-sided with direction assumed from previous association. 
Table 2 Previously reported associations replicated in the meta-analysis 
      All cases ER negative cases ER positive cases
SNP Gene Published Model Effect Allele Effect Allele Freq HR (90% CI) One-sided 
p-value
HR (90% CI) One-sided 
p-value
HR (90% CI) One-sided  
p-value 
rs2981582 FGFR2 Bayraktar et al. [33] Dominance G 0.57 1.09 (1.04-1.14) 0.00085 1.08 (1.00-1.16) 0.052 1.04 (0.98-1.10) 0.15 
rs1800566 NQO1 Fagerholm et al. [13] Dominance A 0.19 1.10 (1.03-1.17) 0.0046 1.14 (1.03-1.25) 0.015 1.04 (0.95-1.13) 0.23
rs9934948 LOC100506172 Shu et al. [6] (GWAS) Co-dominance T 0.15 0.92 (0.86-0.98) 0.011 0.90 (0.79-1.01) 0.059 0.95 (0.86-1.04) 0.18 
rs1800470 TGF Shu et al. [6] Co-dominance A 0.61 0.95 (0.91-0.99) 0.030 0.96 (0.88-1.04) 0.20 0.95 (0.88-1.02) 0.12 
rs3775775 SULT1E1 Choi et al. [46] Dominance G 0.09 1.08 (1.00-1.16) 0.046 1.17 (1.03-1.31) 0.02 1.06 (0.95-1.17) 0.18 
rs700519 CYP19A1 Long et al. [54] Dominance A 0.03 1.10 (0.98-1.22) 0.093 1.03 (0.83-1.23) 0.40 1.30 (1.10-1.50) 0.0050
rs731236 VDR Perna et al. [65] Co-dominance G 0.39 1.04 (1.00-1.08) 0.056 1.03 (0.95-1.11) 0.28 1.09 (1.02-1.16) 0.017
rs12900137 CYP19A1 Long et al. [54] Dominance C 0.05 1.01 (0.91-1.11) 0.47 0.94 (0.78-1.10) 0.70 1.18 (1.02-1.34) 0.032
rs10477313 PPP2R2B Jamshidi et al. [34] Dominance T 0.12 0.94 (0.87- 1.01) 0.08 0.92 (0.79-1.05) 0.15 0.88 (0.77-0.99) 0.035
rs2333227 MPO Ambrosone et al. [44] Dominance T 0.21 1.03 (0.97-1.09) 0.20 0.95 (0.87-1.03) 0.78 1.09 (1.01-1.17) 0.036
rs1902586 CYP19A1 Long et al. [54] Dominance A 0.05 1.01 (0.91-1.11) 0.44 0.99 (0.83-1.15) 0.54 1.16 (1.01-1.31) 0.041
rs28566535 CYP19A1 Long et al. [54] Dominance C 0.05 1.00 (0.90-1.10) 0.51 0.97 (0.81-1.13) 0.60 1.15 (1.00-1.30) 0.046
Hazard ratios are for breast cancer specific survival using a Cox proportional hazards model corrected for principal components. 
Hazard ratios, confidence intervals and p-values are from a co-dominant model. 
P-values refer to a one-sided test of association in the direction indicated in bold in the 90% CI of the HR. 
P-values in bold indicate results that are nominally significant (P<0.05). 
Discussion 
There have been few studies focussed on the replication of sub-genome-wide significant 
associations identified previously. Previous replication studies have focussed on reporting the 
SNPs with the strongest evidence of association. We have found some evidence to support 
previously reported associations between common germline genetic variants and breast 
cancer prognosis. However, the moderate evidence for some variants provides a rationale for 
continued research efforts to identify such variants. Significant variants were for the most 
part candidates in cancer-related genes as is shown in Table 1. Despite the larger sample size 
and therefore increased power to detect true associations with prognosis in comparison to 
previous studies, a possible reason for associations failing to reach genome-wide significance 
may still be limited power. Figure 2a illustrates that for our analysis with 2,900 survival 
events from 37,954 cases, there is limited power to detect associations at stringent 
significance levels for modest effect sizes based on a variant with a 0.3 minor allele 
frequency. Figure 2b shows that almost five times as many events would be needed to detect 
with 80 per cent power at p-value < 10−8 an allele with a minor allele frequency of 0.3 that 
confers a hazard ratio of 1.1. 
Figure 2 Power(%) to detect true associations with survival-time across a range of minor 
allele frequencies and numbers of events. a. Power(%) to detect true associations with 
survival-time over a range of effect sizes at increasing orders of significance given a minor 
allele frequency of 0.3 and 2,900 events. We used an imputation r2 = 0.8 to account for 
suboptimal imputation. b. Power(%) to detect true associations with survival-time for 
increasing numbers of events, at increasing orders of significance, given a minor allele 
frequency of 0.3 and an effect size of 1.1. We used an imputation r2 = 0.8 to account for 
suboptimal imputation. 
In a two-sided test, five of the previously reported associations with prognosis were 
significantly associated with breast cancer specific survival in the GWAS meta-analysis but 
had discordant directions of effect to the original results. These discrepancies may be caused 
by differing ethnicity between the sample populations [20] as the meta-analysis is specific to 
patients with European ancestry whereas the five original studies consider non-European 
populations [6,21-23]. On the other hand they may also represent false positive associations 
in both discovery and replication data. 
Many previously published studies used a dominance model to evaluate associations. We 
only used a co-dominant model to detect association in the GWAS. This is justified because 
thousands of common variants [24] associated with a range of diseases have been identified 
using a co-dominant model with little or no evidence for dominance. It seems unlikely that 
breast cancer survival would differ substantially from other phenotypes in any true, 
underlying genetic model. Where the true underlying model is co-dominant this approach 
will maximise statistical power. While it is possible, that some variants may be truly 
associated under a dominance model, e.g. through loss of heterozygosity of the specific 
germline variant in the tumour, we would still have reasonable power to detect such an 
association with the large sample size of the GWAS under a co-dominant model. 
A further way to increase power to detect robust associations with prognosis is to reduce the 
level of heterogeneity in the phenotype. Studies focussing on identifying subtype specific 
associations will have increased power to detect variants associated with a particular subtype 
than an analysis on all patients will have. In particular, studies considering disease subtypes, 
eg. ER negative disease, may provide valuable information into the reasons for known 
prognostic differences between subtypes. We identified 7 SNPs associated with ER-positive 
disease. These SNPs were not previously identified in specifically ER positive disease, 
however, our observations may agree with the previously reported results as most breast 
cancers are ER positive. In addition, studies looking at interactions with specific treatments, 
most notably adjuvant chemotherapy, hormonal therapy and adjuvant radiotherapy, may 
further inform targeted treatment of subgroups of patients according to their inherited genetic 
information. Some of the previously reported associations with prognosis were found in 
specific subgroups of patients; however as yet the sizes of these studies are limited. Large 
subtype-specific studies are needed in order to investigate interactions with particular 
subgroups effectively. The generation of sufficiently large studies to deliver strongly 
significant results as well as having good outcome and treatment data to enable powerful 
subtype specific analyses, will only be possible by combining data resources through large-
scale global collaborations. Case–control studies including approximately 100,000 cases are 
now being conducted to identify common variants associated with risk. It seems a realistic 
goal to carry out case-cohort studies of a similar size. Reliable identification of SNPs 
associated with breast cancer prognosis may help to understand the molecular mechanisms of 
tumour progression and metastasis. Ultimately, this may lead to the development of new 
therapeutic targets. Polygenic risk scores based on multiple risk alleles have been shown to 
have potentially useful discrimination [25]. Similar polygenic prognostic scores may improve 
discrimination of prognostic and treatment benefit tools such as PREDICT [26]. 
Conclusions 
We have found limited evidence to support the assertion that germline genetic variation 
influences outcome after a diagnosis of breast cancer. Large studies with detailed clinical and 
follow-up information are needed in order to achieve sufficient statistical power to detect 
associations at stringent significance thresholds. In addition, power can also be increased by 
reducing the level of phenotype heterogeneity which will also provide valuable insights into 
prognostic differences between subgroups. 
Abbreviations 
BCSS, Breast cancer specific survival; CI, Confidence interval; COGS, Collaborative 
Oncological Gene-environment Study; ER, Oestrogen receptor; GWAS, Genome-wide 
association study(studies); HER2, Human epidermal growth factor receptor 2; SNP, Single 
nucleotide polymorphism. 
Competing interests 
The authors declare they have no competing interests. 
  
Authors’ contributions 
AP, PDP, MS and PAF conceived of the study. The data analysis was done by QG, AP, CC, 
SK, KM and JT. The data management was conducted by KM, ML, MKB, QW and JD. The 
manuscript was drafted by AP, PDP and MS and all authors contributed to the editing and 
critical review. The sample collection for the participating studies was conducted by: PK, 
BEH, CH, FS, LM, JF, RY, DC, RD, SG, MMG, SH, RH, AH, RK, MM, WW, MB, FC 
(BPC3); PDP, AD, MiS (SEARCH); KC, HD, ME (pKarma); DL, CW, KL, CO (LMBC); 
SEB, BN, SFN, HF(CGPS); JC, AR, PS, DF (MARIE); HN, CB, KA, RF, TM (HEBCS); 
FJC, JO, EH, CV (MCBCS); IA, JK, GG, AMM (OFBCR); CH, BEH, FS, LM(MEC); MS, 
SaC, AB, FH, StC (ABCS); JH, HT, CA, MCS(ABCFS); AC, SC, MR(SBCS); GGG, RM, 
CM (MCCS); RW, KP, AJV, MG (OBCS); MH, AnH, JM, AO (RBCS); MGC, SJC, JoL, JF 
(PBCS); FM, AS, RonY, BB (BSUCH); ES, IT, MK, NM (BIGGS); HB, KB, BH 
(ESTHER); AM, VeK, VmK, JMH (KBCP); PH, JiL, JSB, KH (SASBAC); PD, RT, CS 
(ORIGO); PR, PP, SM, FF (MBCSG); PF, MWB, AlH, AE (BBCC); GC, RB, KAP 
(kConFab /AOCS); JB, PZ, JIAP, PM (CNIO-BCS); AJ, JL, JG, KD (SZBCS); UH, MaK, 
HU, TR (SKKDKFZS); SaM (KARBAC); VK, SN (NBCS); DiE, NR, GE (UK2); JA, HE, 
CP, LH, JAD, SB (PGSNPs); SFC, CaC (METABRIC); DH, SL (NHS); DE (BCAC). All 
authors read and approved the final draft of the manuscript. 
Acknowledgements 
This study would not have been possible without the contributions of the following: D. C. 
Tessier, F. Bacot, D. Vincent,, S. LaBoissière and F. Robidoux and the staff of the 
genotyping unit, (Genome Quebec); J. Stone, S. McBean, J. Hadlington, A. Mustafa and K. 
Cook (Illumina); M. Angelakos, J. Maskiell, G. Dite, T. Selander, N. Weerasooriya 
(ABCFS); R. van Hien, L. Braaf, F. Hogervorst, S. Verhoef, E. Rutgers, F. Atsma (ABCS); 
N. McInerney, G. Colleran, A. Rowan, A. Jones (BIGGS); P. Bugert (BSUCH); D. U. 
Andersen, M. B. Arnadottir, A. Bank, D. K. Hansen (CGPS); G. Pita, C. Alonso, D. Herrero, 
N. Álvarez (CNIO-BCS); H. Ziegler, S. Wolf, V. Hermann (ESTHER); D. Greco, K. von 
Smitten, I. Erkkilä, T. Heikkinen, K. Aaltonen (HEBCS); E. Myöhänen, H. Kemiläinen 
(KBCP); G. Peuteman, D. Smeets, T. Van Brussel, K. Corthouts (LMBC); Judith Heinz, 
Nadia Obi, Alina Vrieling, Sabine Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers 
(MARIE); B. Peissel, G. Scuvera, D. Zaffaroni, M. Barile, I. Feroce (MBCSG); K. Mononen, 
M. Otsukka (OBCS); T. Selander, N. Weerasooriya (OFBCR); E. Krol-Warmerdam, J. Blom. 
J. Molenaar (ORIGO); L. Brinton, M. Sherman, N. Szeszenia-Dabrowska, B. Peplonska, W. 
Zatonski, P. Chao, M. Stagner (PBCS); P. Bos, J. Blom, E. Crepin, A. Nieuwlaat, A. 
Heemskerk (RBCS); S. Higham, Ian Brock, Sabapathy Balasubramanian, Dan Connley, 
Helen Cramp (SBCS); J.Young, C. Twelves, AL. Vallier, S. Ingle, R. Hardy (PGSNPS); 
Matthias Rübner, Silke Landrith, Sonja Oeser, Lothar Häberle (BBCC). 
  
References 
1. IARC. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. 
2. Hartman M, Lindström L, Dickman PW, Adami H-O, Hall P, Czene K. Is breast cancer 
prognosis inherited? Breast Cancer Res. 2007;9:R39. 
3. Ribelles N, Santonja A, Pajares B, Llácer C, Alba E. The seed and soil hypothesis 
revisited: current state of knowledge of inherited genes on prognosis in breast cancer. Cancer 
Treat Rev. 2014;40:293–9. 
4. Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, Schulz-Wendtland R, et al. 
Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen 
receptor-negative breast cancer survival. J Natl Cancer Inst. 2010;102:650–62. 
5. Azzato EM, Pharoah PDP, Harrington P, Easton DF, Greenberg D, Caporaso NE, et al. A 
genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers 
Prev. 2010;19:1140–3. 
6. Shu XO, Long J, Lu W, Li C, Chen WY, Delahanty R, et al. Novel genetic markers of 
breast cancer survival identified by a genome-wide association study. Cancer Res. 
2012;72:1182–9. 
7. Fasching P, Pharoah PDP, Cox A, Nevanlinna H, Bojesen SE, Karn T, et al. The role of 
genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet. 
2012;21:3926–39. 
8. Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, et al. Replication of genetic 
polymorphisms reported to be associated with taxane-related sensory neuropathy in patients 
with early breast cancer treated with Paclitaxel. Clin Cancer Res. 2014;20:2466–75. 
9. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic 
and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 
2012;486:346–52. 
10. Earl HM, Vallier A-L, Hiller L, Fenwick N, Young J, Iddawela M, et al. Effects of the 
addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, 
cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-
tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol. 2014;15:201–
12. 
11. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG. Prospective study of 
Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer. 
2007;7:160. 
12. Einarsdóttir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, et al. ESR1 and EGF genetic 
variation in relation to breast cancer risk and survival. Breast Cancer Res. 2008;10:R15. 
13. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, et al. 
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and 
predictive factor in breast cancer. Nat Genet. 2008;40:844–53. 
14. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide 
association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal 
breast cancer. Nat Genet. 2007;39:870–4. 
15. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. 
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 
2013;45:353–61. 
16. Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, et al. tAnGo: A 
randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, 
epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-
stage breast cancer (EBC). ASCO Meet Abstr. 2008;26:506. 
17. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and 
cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. 
N Engl J Med. 2006;355:1851–62. 
18. Siddiq A, Couch FJ, Chen GK, Lindström S, Eccles D, Millikan RC, et al. A meta-
analysis of genome-wide association studies of breast cancer identifies two novel 
susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012;21:5373–84. 
19. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 
1,092 human genomes. Nature. 2012;491:56–65. 
20. Bryant EK, Dressen AS, Bunker CH, Hokanson JE, Hamman RF, Kamboh MI, et al. A 
multiethnic replication study of plasma lipoprotein levels-associated SNPs identified in recent 
GWAS. PLoS One. 2013;8, e63469. 
21. Long J-R, Cai Q, Shu X-O, Cai H, Gao Y-T, Zheng W. Genetic polymorphisms in 
estrogen-metabolizing genes and breast cancer survival. Pharmacogenet Genomics. 
2007;17:331–8. 
22. Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, et al. Matrix 
metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer 
Health Disparities Study. PLoS One. 2013;8, e63165. 
23. You Y, Deng J, Zheng J, Hu M, Li N, Wu H, et al. IL-21 gene polymorphism is 
associated with the prognosis of breast cancer in Chinese populations. Breast Cancer Res 
Treat. 2013;137:893–901. 
24. Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European 
Bioinformatics Institute), Junkins HA, Hall PN, Klemm AK and MT: A Catalog of Published 
Genome-Wide Association Studies. Available at: www.genome.gov/gwastudies Accessed 22 
Aug 2013 . 
25. Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, risk prediction, and 
targeted prevention of breast cancer. N Engl J Med. 2008;358:2796–803. 
26. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. 
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive 
breast cancer. Breast Cancer Res. 2010;12:R1. 
27. Bewick MA, Conlon MSC, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and 
CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol. 
2006;24:5645–51. 
28. Bewick MA, Lafrenie RM, Conlon MSC. Nucleotide excision repair polymorphisms and 
survival outcome for patients with metastatic breast cancer. J Cancer Res Clin Oncol. 
2011;137:543–50. 
29. Castro E, Olmos D, Garcia A, Cruz JJ, González-Sarmiento R. Role of XRCC3, XRCC1 
and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant 
chemotherapy in early stage breast cancer patients. Clin Transl Oncol. 2014;16:158–65. 
30. Goode EL, Dunning AM, Kuschel B, Study P, Healey CS, Day NE, Ponder BAJ, Easton 
DF, Pharoah PPD: Effect of Germ-Line Genetic Variation on Breast Cancer Survival in a 
Population-based Study Effect of Germ-Line Genetic Variation on Breast Cancer Survival in 
a. 2002:3052–3057 
31. Lin W-Y, Camp NJ, Cannon-Albright LA, Allen-Brady K, Balasubramanian S, Reed 
MWR, et al. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J 
Med Genet. 2011;48:477–84. 
32. Azzato EM, Driver KE, Lesueur F, Shah M, Greenberg D, Easton DF, et al. Effects of 
common germline genetic variation in cell cycle control genes on breast cancer survival: 
results from a population-based cohort. Breast Cancer Res. 2008;10:R47. 
33. Bayraktar S, Thompson PA, Yoo S-Y, Do K, Sahin AA, Arun BK, et al. The relationship 
between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer 
outcomes. Oncologist. 2013;18:493–500. 
34. Jamshidi M, Schmidt MK, Dörk T, Garcia-Closas M, Heikkinen T, Cornelissen S, et al. 
Germline variation in TP53 regulatory network genes associates with breast cancer survival 
and treatment outcome. Int J Cancer. 2013;132:2044–55. 
35. Pei R, Xu Y, Wei Y, Ouyang T, Li J, Wang T, et al. Association of SIPA1 545 C > T 
polymorphism with survival in Chinese women with metastatic breast cancer. Front Med. 
2013;7:138–42. 
36. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van’t Veer LJ, Pharoah PDP, et 
al. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, 
and p53 expression on survival of breast cancer patients. Breast Cancer Res. 2009;11:R89. 
37. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, et al. Breast cancer 
patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 
2005;11:5098–103. 
38. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, et al. Association of 
TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. 
Breast Cancer Res. 2007;9:R34. 
39. Beeghly-Fadiel A, Shu X-O, Long J, Li C, Cai Q, Cai H, et al. Genetic polymorphisms in 
the MMP-7 gene and breast cancer survival. Int J Cancer. 2009;124:208–14. 
40. Beeghly-Fadiel A, Zheng W, Lu W, Long J, Zheng Y, Cai H, et al. Replication study for 
reported SNP associations with breast cancer survival. J Cancer Res Clin Oncol. 
2012;138:1019–26. 
41. Decock J, Long J-R, Laxton RC, Shu X-O, Hodgkinson C, Hendrickx W, et al. 
Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. 
Cancer Res. 2007;67:10214–21. 
42. Peterson NB, Beeghly-Fadiel A, Gao Y-T, Long J, Cai Q, Shu X, Zheng W: 
Polymorphisms in tissue inhibitors of metalloproteinases −2 and −3 and breast cancer 
susceptibility and survival. Int J Cancer. 2010, 125:844–850. 
43. Zhang X, Shu X-O, Cai Q, Ruan Z, Gao Y-T, Zheng W. Functional plasminogen 
activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res. 
2006;12:6037–42. 
44. Ambrosone CB, Ahn J, Singh KK, Furberg H, Sweeney C, Coles B, Trovato A: 
Polymorphisms in Genes Related to Oxidative Stress ( MPO , MnSOD , CAT ) and Survival 
After Treatment for Breast Cancer CAT ) and Survival After Treatment for Breast Cancer. 
2005:1105–1111. 
45. Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, et al. CD24 polymorphisms in 
breast cancer: impact on prognosis and risk. Breast Cancer Res Treat. 2013;137:927–37. 
46. Choi J-Y, Lee K-M, Park SK, Noh D-Y, Ahn S-H, Chung H-W, et al. Genetic 
polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. 
Cancer Epidemiol Biomarkers Prev. 2005;14:1090–5. 
47. Demichele A, Martin A, Mick R, Gor P, Wray L, Klein-cabral M, Athanasiadis G, 
Colligan T, Stadtmauer E, Weber B: Interleukin-6 ؊ 174G3 C Polymorphism Is Associated 
with Improved Outcome in High-Risk Breast Cancer. 2003:8051–8056. 
48. Duggan C, Ballard-Barbash R, Baumgartner RN, Baumgartner KB, Bernstein L, 
McTiernan A. Associations between null mutations in GSTT1 and GSTM1, the GSTP1 
Ile(105)Val polymorphism, and mortality in breast cancer survivors. Springerplus. 
2013;2:450. 
49. Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, et al. Single 
nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and 
prognosis in breast cancer patients. Breast Cancer Res Treat. 2008;112:89–98. 
50. Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, et al. 
Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res 
Treat. 2010;119:701–5. 
51. Hartikainen JM, Tengström M, Kosma V-M, Kinnula VL, Mannermaa A, Soini Y. 
Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival 
outcomes in breast cancer. Cancer Res. 2012;72:5537–46. 
52. Jiang L, Deng J, Zhu X, Zheng J, You Y, Li N, et al. CD44 rs13347 C>T polymorphism 
predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res. 
2012;14:R105. 
53. Lee J-H, Kim Y, Choi J-W, Kim Y-S. Clinicopathological significance of plasminogen 
activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Arch 
Med Res. 2013;44:39–45. 
54. Long J-R, Kataoka N, Shu X-O, Wen W, Gao Y-T, Cai Q, et al. Genetic polymorphisms 
of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev. 
2006;15:2115–22. 
55. Sweeney C, Mcclure GY, Fares MY, Ile SP, Polymorphism V, Stone A, Coles BF, 
Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB: Association 
between Survival after Treatment for Breast Cancer and Glutathione S -Transferase P1 Ile 
105 Val Polymorphism Advances in Brief Association between Survival after Treatment for 
Breast Cancer and Glutathione. Cancer Res. 2000:5621–5624. 
56. Yang C-X, Li C-Y, Feng W. Toll-like receptor 4 genetic variants and prognosis of breast 
cancer. Tissue Antigens. 2013;81:221–6. 
57. Choi J-Y, Lee K-M, Noh D-Y, Ahn S-H, Lee J-E, Han W, et al. Genetic polymorphisms 
of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat. 
2006;100:213–8. 
58. Kontogianni P, Zambirinis CP, Theodoropoulos G, Gazouli M, Michalopoulos NV, 
Flessas J, et al. The impact of the stromal cell-derived factor-1-3’A and E-selectin S128R 
polymorphisms on breast cancer. Mol Biol Rep. 2013;40:43–50. 
59. Lu H, Shu X-O, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic 
polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005;65:5015–9. 
60. Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, Kimmig R, et al. The T393C 
polymorphism in the gene GNAS1 of G protein is associated with survival of patients with 
invasive breast carcinoma. Breast Cancer Res Treat. 2007;105:311–7. 
61. Qu S, Long J, Cai Q, Shu X-O, Cai H, Gao Y-T, et al. Genetic polymorphisms of 
metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res. 
2008;14:4787–93. 
62. Shu X-O. Genetic Polymorphisms in the TGF- 1 Gene and Breast Cancer Survival: A 
Report from the Shanghai Breast Cancer Study. Cancer Res. 2004;64:836–9. 
63. Upadhyay R, Sanduja S, Kaza V, Dixon DA. Genetic polymorphisms in RNA binding 
proteins contribute to breast cancer survival. Int J Cancer. 2013;132:E128–38. 
64. Pande M, Thompson PA, Do K-A, Sahin AA, Amos CI, Frazier ML, et al. Genetic 
variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis. 
2013;34:587–94. 
65. Perna L, Butterbach K, Haug U, Schöttker B, Müller H, Arndt V, et al. Vitamin D 
Receptor Genotype rs731236 (Taq1) and Breast Cancer Prognosis. Cancer Epidemiol 
Biomarkers Prev. 2013;22:437–42. 
66. Martin DN, Boersma BJ, Howe TM, Goodman JE, Mechanic LE, Chanock SJ, et al. 
Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer. 
2006;6:257. 


Additional files provided with this submission:
Additional file 1. Study information for GWAS included in meta-analysis [Guo, Schmidt, Pharoah et al., under review]
(31kb)
http://breast-cancer-research.com/content/supplementary/s13058-015-0570-7-s1.pdf
Additional file 2. Samples included in meta-analysis by study [Guo, Schmidt, Pharoah et al. under review] (31kb)
http://breast-cancer-research.com/content/supplementary/s13058-015-0570-7-s2.pdf
Additional file 3. Previously reported associations with breast cancer survival (75kb)
http://breast-cancer-research.com/content/supplementary/s13058-015-0570-7-s3.pdf
Additional file 4. Look- up of previously reported associations in meta-analysis (75kb)
http://breast-cancer-research.com/content/supplementary/s13058-015-0570-7-s4.pdf
Additional file 5. Multivariable analysis results adjusting for age, stage and grade in samples from the COGS dataset (65kb)
http://breast-cancer-research.com/content/supplementary/s13058-015-0570-7-s5.pdf
